Mannatech vs Niagen Bioscience
MTEX and NAGE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MTEX and NAGE compare
Niagen Bioscience is the larger company, worth 13 times as much as Mannatech ($163M against $12.2M).
Niagen Bioscience grew revenue faster over the last twelve months (−1.9% versus −6.6% for Mannatech).
Niagen Bioscience keeps more of each dollar of sales as profit, with a net margin of 8.4% compared with −0.41% at Mannatech.
Niagen Bioscience scores higher on the StockData Score (14 against 9 for Mannatech), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MTEX | NAGE |
|---|---|---|
| Size and price | ||
| Market cap | $12.2M | $163M |
| Share price | $6.30 | $2.06 |
| Change, 1 year | −33.8% | −71.2% |
| Change, 5 years | −83.5% | −61.7% |
| Beta (5Y) | 0.36 | 1.05 |
| Employees | 387 | 117 |
| StockData Score | ||
| Total score | 9 | 14 (better) |
| Valuation score | 3 | 3 |
| Growth score | 0 | 1 (better) |
| Performance score | 4 | 4 |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 17.2× |
| P/S | 0.1× (better) | 1.3× |
| P/B | 2.3× | 2.0× (better) |
| EV/EBITDA | 4.8× (better) | 19.7× |
| FCF yield | −5.3% | – |
| Fair value | $11.41 | $2.46 |
| Margin of safety | 44.8% (better) | 16.1% |
| Growth | ||
| Revenue growth (TTM) | −6.6% | −1.9% (better) |
| Revenue growth, 5Y average | −6.5% | 16.9% (better) |
| Net income growth (TTM) | – | −49.9% |
| EPS growth (TTM) | – | −50.0% |
| Profitability | ||
| Gross margin | 75.7% (better) | 63.9% |
| Operating margin | 0.91% | 3.9% (better) |
| Net margin | −0.41% | 8.4% (better) |
| FCF margin | −0.63% | – |
| Return on equity | −7.0% | 13.3% (better) |
| Return on invested capital | 17.8% | 44.3% (better) |
| Financial health | ||
| Debt / equity | 0.53 (better) | 0.00 |
| Net debt / EBITDA | −1.36 | – |
| Interest coverage | 2.0× | – |
| Current ratio | 1.18 | 5.93 (better) |
| Altman Z-score | 4.10 (better) | 3.98 |
| Piotroski F-score | 2 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.3% |
| Shareholder yield | 0.00% | 3.3% (better) |
| Ownership | ||
| Held by institutions | 7.9% | 40.4% |
| Held by insiders | – | 5.1% |
| Insider net buying, 12 months | $62.2K (better) | $0 |
| Short interest, % of float | – | 5.8% |
Go deeper
- MTEX stock overview
- MTEX income statement
- MTEX valuation and score
- NAGE stock overview
- NAGE income statement
- NAGE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.